Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

27.89 +0.10 (+0.36%)
Streaming Delayed Price Updated: 12:55 PM EDT, Sep 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
2025 R&D Spending And Intensity Benchmarks
Via PRLog
Topics Supply Chain
News headline image
Why Pfizer Stock Was so Healthy in August ↗
The beaten-down pharmaceutical stock was revived after it posted an estimates-beating quarter. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now ↗
Pfizer's 6% dividend yield is enticing, but AbbVie's dividend growth is superior. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
News headline image
Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock? ↗
The big story today with Eli Lilly is its hugely successful GLP-1 drugs, but the long-term story is likely to be about its acquisitions. 
Via The Motley Fool
News headline image
This Is What I'd Do With Pfizer Stock Right Now ↗
The pharmaceutical stock is struggling, but its dividend can be highly valuable to income investors. 
Via The Motley Fool
Topics Intellectual Property
News headline image
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗
AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Things You Need to Know If You Buy Pfizer Stock Today ↗
After a long bout with poor post-pandemic performance, the stock's starting to perk up. The question is, are other investors -- and analysts -- willing to stick their neck out any further anytime... 
Via The Motley Fool
Topics Intellectual Property
News headline image
Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion ↗
Medicus Pharma partners with Pfizer to commercialize CD228V in a licensing deal worth over $1 billion plus royalties. 
Via Benzinga
News headline image
Is BioNTech Stock a No-Brainer Buy on the Dip? ↗
The company is coming back into the spotlight thanks to recent developments. 
Via The Motley Fool
Wednesday's session: most active stock in the S&P500 index ↗
Via Chartmill
News headline image
Should You Buy Pfizer Stock Below $30? ↗
Patient investors who buy the stock may be rewarded over the long term. 
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
2 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now ↗
If you're looking to invest $1,000 in a dividend stock, look to the pharmaceutical sector. 
Via The Motley Fool
News headline image
Top Companies Using Salesforce CRM in the USA ↗
Salesforce powers the engine behind America’s most ambitious brands. From retail giants to global banks, its footprint is massive. Therefore, marketers eve 
Via Talk Markets
Curious about the most active S&P500 stocks in today's session? ↗
Via Chartmill
Stay informed about the most active stocks in the S&P500 index on Monday's session. ↗
Via Chartmill
News headline image
3 Stocks for Investors Who Still Believe Cash Is King ↗
As investors hedge against AI-trade valuation worries, dividend payers gain favor. AT&T, ONEOK, and Pfizer offer yields from 4.3% to 6.1% with distinct capital-return strategies. 
Via MarketBeat
Topics Artificial Intelligence ETFs Economy
News headline image
3 Cash-Producing Stocks That Concern Us
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
News headline image
Should Eli Lilly Investors Be Worried About a Threat From Amylyx? ↗
Eli Lilly is currently leading the GLP-1 market, but Amylyx is seeing strong results from its GLP-1 drug candidate. 
Via The Motley Fool
News headline image
Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable. 
Via The Motley Fool
News headline image
2 Cash-Producing Stocks with Solid Fundamentals and 1 We Turn Down
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc... 
Via StockStory
News headline image
QUICK SPARK: FDA Approves Updated COVID Vaccines From Moderna, Pfizer, Novavax ↗
FDA approves updated COVID-19 vaccines for 2026-'27 season, targeting XFG variant. Limited eligibility for adults 65+ and those with high-risk conditions. 
Via Benzinga
News headline image
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
From Pfizer Inc.
Via Business Wire
News headline image
The Most Concerning Thing About Pfizer's Dividend Isn't What You Think ↗
Pfizer's payout ratio is above 100%, but that's not the number you should probably be watching right now. 
Via The Motley Fool
Topics Intellectual Property
Explore the S&P500 index on Wednesday and find out which stocks are the most active in today's session. ↗
Via Chartmill
News headline image
My 2 Favorite Dividend Stocks to Buy in August ↗
These are two stocks that pay investors a regular income. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Dividend Stocks to Hold for the Next 10 Years ↗
These healthcare leaders are unlikely to suspend their dividend programs. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
Q2 Rundown: Pfizer (NYSE:PFE) Vs Other Branded Pharmaceuticals Stocks
Let’s dig into the relative performance of Pfizer (NYSE:PFE) and its peers as we unravel the now-completed Q2 branded pharmaceuticals earnings season. Lookin... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
D-Wave Quantum vs. Rigetti Computing: Which Quantum Computing Stock Is a Better Investment in 2026? ↗
While both D-Wave and Rigetti's revenues have been volatile, their valuations tell a starkly different story for quantum investors. 
Via The Motley Fool
News headline image
Prediction: This Is Where Pfizer Stock Will Be in 2030 ↗
Pfizer is facing material patent expirations over the next two years, but that will be over by 2030. 
Via The Motley Fool
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.